E-cadherin: A potential biomarker of colorectal cancer prognosis

Oncology Letters

Volumn 13, Issue 6, 2017, Pages 4571-4576

  Christou, Niki ^a,b   Perraud, Aurélie ^a,b   Blondy, Sabrina ^a   Jauberteau, Marie Odile ^a   Battu, Serge ^a,b   Mathonnet, Muriel ^a,b  

^a UNIVERSITY OF LIMOGES   (France)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

Biomarkers; Colorectal cancer; E cadherin protein

Indexed keywords

ALPHA CATENIN; BETA CATENIN; CALCIUM; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE B; MATRILYSIN; MATRIX METALLOPROTEINASE; MEMBRANE PROTEIN; PLAKOGLOBIN; PROTEIN TYROSINE PHOSPHATASE SHP; SNAI1 PROTEIN; STRATUM CORNEUM CHYMOTRYPTIC ENZYME; STROMELYSIN; SYNDECAN 2; UNCLASSIFIED DRUG; UVOMORULIN; VITAMIN D;

CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CELL ADHESION; COLORECTAL CANCER; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METASTASIS; MUTATION; O MANNOSYLATION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW;

EID: 85019652199     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2017.6063     Document Type: Review

References (51)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136: E359-E386, 2015.
2. Faivre J, Lepage C and Viguier J: Cancer colorectal: Du diagnostic au dépistage. Gastroentérologie Clin Biol 33: 660-671, 2009.
3. Institut National Du Cancer (INCA): Les traitements du cancer du côlon, collection Guides patients Cancer info. INCA, 2010. http://www.e-cancer.fr/Patients-et-proches/Les-cancers/Cancer-du-colon/Points-cles.
4. Rawson JB and Bapat B: Epigenetic biomarkers in colorectal cancer diagnostics. Expert Rev Mol Diagn 12: 499-509, 2012.
5. Hatakeyama K, Wakabayashi-Nakao K, Ohshima K, Sakura N, Yamaguchi K and Mochizuki T: Novel protein isoforms of carcinoembryonic antigen are secreted from pancreatic, gastric and colorectal cancer cells. BMC Res Notes 6: 381, 2013.
6. Gold P and Freedman SO: Specific carcinoembryonic antigens of the human digestive system. J Exp Med 122: 467-481, 1965.
7. Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG and Somerfield MR; American Society of Clinical Oncology Tumor Markers Expert Panel: 2000, Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American society of clinical oncology. J Clin Oncol 19: 1865-1878, 2001.
8. Yörüker EE, Holdenrieder S and Gezer U: Blood-based biomarkers for diagnosis, prognosis and treatment of colorectal cancer. Clin Chim Acta 455: 26-32, 2016.
9. Fan F, Samuel S, Evans KW, Lu J, Xia L, Zhou Y, Sceusi E, Tozzi F, Ye XC, Mani SA and Ellis LM: Overexpression of Snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells. Cancer Med 1: 5-16, 2012.
10. Newton KF, Newman W and Hill J: Review of biomarkers in colorectal cancer. Colorectal Dis 14: 3-17, 2012.
11. Wang B and Zhang Q: The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol 138: 1659-1666, 2012.
12. Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC, et al: Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 20: 1223-1229, 2009.
13. Taback B, Saha S and Hoon DS: Comparative analysis of mesenteric and peripheral blood circulating tumor DNA in colorectal cancer patients. Ann N Y Acad Sci 1075: 197-203, 2006.
14. Bazan V, Bruno L, Augello C, Agnese V, Calò V, Corsale S, Gargano G, Terrasi M, Schirò V, Di Fede G, et al: Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. Ann Oncol 17 (Suppl 7): vii84-vii90, 2006.
15. Rahbari NN, Aigner M, Thorlund K, Mollberg N, Motschall E, Jensen K, Diener MK, Büchler MW, Koch M and Weitz J: Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology 138: 1714-1726, 2010.
16. Abdallah EA, Fanelli MF, Buim ME, Machado Netto MC, Gasparini Junior JL, Souza E Silva V, Dettino AL, Mingues NB, Romero JV, Ocea LM, et al: Thymidylate synthase expression in circulating tumor cells: A new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients. Int J Cancer 137: 1397-1405, 2015.
17. Lecomte T, Berger A, Zinzindohoué F, Micard S, Landi B, Blons H, Beaune P, Cugnenc PH and Laurent-Puig P: Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 100: 542-548, 2002.
18. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF and Bast RC Jr; ASCO: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24: 5313-5327, 2006.
19. Behrens J: The role of cell adhesion molecules in cancer invasion and metastasis. Breast Cancer Res Treat 24: 175-184, 1993.
20. Shiozaki H, Oka H, Inoue M, Tamura S and Monden M: E-cadherin mediated adhesion system in cancer cells. Cancer 77: 1605-1613, 1996.
21. Nagar B, Overduin M, Ikura M and Rini JM: Structural basis of calcium-induced E-cadherin rigidification and dimerization. Nature 380: 360-364, 1996.
22. Van Roya F and Berxb G: The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci 65: 3756-3788, 2008.
23. Aberle H, Schwartz H and Kemler R: Cadherin-catenin complex: Protein interactions and their implications for cadherin function. J Cell Biochem 61: 514-523, 1996.
24. Shapiro L, Fannon AM, Kwong PD, Thompson A, Lehmann MS, Grübel G, Legrand JF, Als-Nielsen J, Colman DR and Hendrickson WA: Structural basis of cell-cell adhesion by cadherins. Nature 374: 327-337, 1995.
25. Canel M, Serrels A, Frame MC and Brunton VG: E-cadherin-integrin crosstalk in cancer invasion and metastasis. J Cell Sci 126: 393-401, 2013.
26. Liu DS, Hoefnagel SJM, Fisher OM, Krishnadath KK, Montgomery KG, Busuttil RA, Colebatch AJ, Read M, Duong CP, Phillips WA and Clemons NJ: Novel metastatic models of esophageal adenocarcinoma derived from FLO-1 cells highlight the importance of E-cadherin in cancer metastasis. Oncotarget 7: 83342-83358, 2016.
27. Strathdee G: Epigenetic versus genetic alterations in the inactivation of E-cadherin. Semin Cancer Biol 12: 373-379, 2002.
28. Vécsey-Semjén B, Becker KF, Sinski A, Blennow E, Vietor I, Zatloukal K, Beug H, Wagner E and Huber LA: Novel colon cancer cell lines leading to better understanding of the diversity of respective primary cancers. Oncogene 21: 4646-4662, 2002.
29. Kanazawa T, Watanabe T, Kazama S, Tada T, Koketsu S and Nagawa H: Poorly differentiated adenocarcinoma and mucinous carcinoma of the colon and rectum show higher rates of loss of heterozygosity and loss of E-cadherin expression due to methylation of promoter region. Int J Cancer 102: 225-229, 2002.
30. Cheng CW, Wu PE, Yu JC, Huang CS, Yue CT, Wu CW and Shen CY: Mechanisms of inactivation of E-cadherin in breast carcinoma: Modification of the two-hit hypothesis of tumor suppressor gene. Oncogene 20: 3814-3823, 2001.
31. Shen Y, Hirsch DS, Sasiela CA and Wu WJ: Cdc42 Regulates E-cadherin ubiquitination and degradation through an epidermal growth factor receptor to Src-mediated pathway. J Biol Chem 283: 5127-5137, 2008.
32. Symowicz J, Adley BP, Gleason KJ, Johnson JJ, Ghosh S, Fishman DA, Hudson LG and Stack MS: Engagement of collagen-binding integrins promotes matrix metallopro-teinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res 67: 2030-2039, 2007.
33. Johnson SK, Ramani VC, Hennings L and Haun RS: Kallikrein 7 enhances pancreatic cancer cell invasion by shedding E-cadherin. Cancer 109: 1811-1820, 2007.
34. Trillsch F, Kuerti S, Eulenburg C, Burandt E, Woelber L, Prieske K, Eylmann K, Oliveira-Ferrer L, Milde-Langosch K and Mahner S: E-cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer. Br J Cancer 114: 213-220, 2016.
35. Jang B, Jung H, Chung H, Moon BI and Oh ES: Syndecan-2 enhances E-cadherin shedding and fibroblast-like morphological changes by inducing MMP-7 expression in colon cancer cells. Biochem Biophys Res Commun 477: 47-53, 2016.
36. Carvalho S, Oliveira T, Bartels MF, Miyoshi E, Pierce M, Taniguchi N, Carneiro F, Seruca R, Reis CA, Strahl S and Pinho SS: O-mannosylation and N-glycosylation: Two coordinated mechanisms regulating the tumour suppressor functions of E-cadherin in cancer. Oncotarget 7: 65231-652446, 2016.
37. Petrova YI, Schecterson L and Gumbiner BM: Roles for E-cadherin cell surface regulation in cancer. Mol Biol Cell 27: 3233-3244, 2016.
38. Okugawa Y, Toiyama Y, Inoue Y, Iwata T, Fujikawa H, Saigusa S, Konishi N, Tanaka K, Uchida K and Kusunoki M: Clinical significance of serum soluble E-cadherin in colorectal carci-noma1. J Surg Res 175: e67-e73, 2012.
39. Efstathiou JA, Liu D, Wheeler JM, Kim HC, Beck NE, Ilyas M, Karayiannakis AJ, Mortensen NJ, Kmiot W, Playford RJ, et al: Mutated epithelial cadherin is associated with increased tumorigenicity and loss of adhesion and of responsiveness to the motogenic trefoil factor 2 in colon carcinoma cells. Proc Natl Acad Sci 96: 2316-2321, 1999.
40. Kitadai Y, Bucana CD, Ellis LM, Anzai H, Tahara E and Fidler IJ: In situ mRNA hybridization technique for analysis of metastases related genes in human colon carcinoma cells 147: 1238-1247, 1995.
41. Gofuku J, Shiozaki H, Tsujinaka T, Inoue M, Tamura S, Doki Y, Matsui S, Tsukita S, Kikkawa N and Monden M: Expression of E-cadherin and alpha-catenin in patients with colorectal carcinoma. Correlation with cancer invasion and metastasis. Am J Clin Pathol 111: 29-37, 1999.
42. Velikova G, Banks RE, Gearing A, Hemingway I, Forbes MA, Preston SR, Hall NR, Jones M, Wyatt J, Miller K, et al: Serum concentrations of soluble adhesion molecules in patients with colorectal cancer. Br J Cancer 77: 1857-1863, 1998.
43. Wilmanns C, Grossmann J, Steinhauer S, Manthey G, Weinhold B, Schmitt-Gräff A and von Specht BU: Soluble serum E-cadherin as a marker of tumour progression in colorectal cancer patients. Clin Exp Metastasis 21: 75-78, 2004.
44. Weiss JV, Klein-Scory S, Kübler S, Reinacher-Schick A, Stricker I, Schmiegel W and Schwarte-Waldhoff I: Soluble E-cadherin as a serum biomarker candidate: Elevated levels in patients with late-stage colorectal carcinoma and FAP. Int J Cancer 128: 1384-1392, 2011.
45. Cao H, Xu E, Liu H, Wan L and Lai M: Epithelial-mesenchymal transition in colorectal cancer metastasis: A system review. Pathol Res Pract 211: 557-569, 2015.
46. Wang R, Ma X, Li Y, He Y, Huang D, Cai S and Peng J: The characteristics and prognostic effect of E-cadherin expression in colorectal signet ring cell carcinoma. PLOS One 11: e0160527, 2016.
47. Gao M, Zhang X, Li D, He P, Tian W and Zeng B: Expression analysis and clinical significance of eIF4E, VEGF-C, E-cadherin and MMP-2 in colorectal adenocarcinoma. Oncotarget 7: 85502-85514, 2016.
48. Chen D, Dai F, Chen Z, Wang S, Cheng X, Sheng Q, Lin J and Chen W: Dimethoxy curcumin induces apoptosis by suppressing survivin and inhibits invasion by enhancing E-cadherin in colon cancer cells. Med Sci Monit 22: 3215-3222, 2016.
49. Nguyen L, Fifis T and Christophi C: Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis. BMC Cancer 16: 533, 2016.
50. Fan LC, Teng HW, Shiau CW, Tai WT, Hung MH, Yang SH, Jiang JK and Chen KF: Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer. Oncotarget 7: 64136-64147, 2016.
51. Liu S, Barry EL, Baron JA, Rutherford RE, Seabrook ME and Bostick RM: Effects of supplemental calcium and vitamin D on the APC/β-catenin pathway in the normal colorectal mucosa of colorectal adenoma patients. Mol Carcinog 56: 412-424, 2017.